Fda Safety Labeling Changes Glp 1 Drugs Eye Diesease Risk ↗
The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss.
Follow the coverage
Fda Safety Labeling Changes Glp 1 Drugs Eye Diesease Risk
Explore articles with matching recorded place and subject information.
Related reporting
Related reporting is temporarily unavailable.